SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Jeff Collins to sit on a panel titled "Investing in Neurotech" at The Neurotech Industry Investing and Partnering Conference in Boston, MA
News | 05. 08. 2008
